Standout Papers

Global burden of NAFLD and NASH: trends, predictions, risk factors a... 2013 2026 2017 2021 3.7k
  1. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention (2017)
    Zobair M. Younossi, Quentin M. Anstee et al. Nature Reviews Gastroenterology & Hepatology
  2. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis (2013)
    Quentin M. Anstee, Giovanni Targher et al. Nature Reviews Gastroenterology & Hepatology
  3. From NASH to HCC: current concepts and future challenges (2019)
    Quentin M. Anstee, Helen L. Reeves et al. Nature Reviews Gastroenterology & Hepatology
  4. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease (2019)
    Peter Eddowes, M. Sasso et al. Gastroenterology
  5. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases (2017)
    Leon A. Adams, Quentin M. Anstee et al. Gut
  6. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management (2014)
    Stuart McPherson, Timothy Hardy et al. Journal of Hepatology
  7. Cellular senescence drives age-dependent hepatic steatosis (2017)
    Mikołaj Ogrodnik, Satomi Miwa et al. Nature Communications
  8. Association Between Fibrosis Stage and Outcomes of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis (2020)
    Rod S Taylor, Rebecca J. Taylor et al. Gastroenterology
  9. Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research (2006)
    Quentin M. Anstee, Robert Goldin International Journal of Experimental Pathology
  10. Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis (2016)
    Stuart McPherson, Timothy Hardy et al. The American Journal of Gastroenterology
  11. Nonalcoholic Fatty Liver Disease: Pathogenesis and Disease Spectrum (2016)
    Timothy Hardy, Fiona Oakley et al. Annual Review of Pathology Mechanisms of Disease
  12. TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease (2014)
    Yang‐Lin Liu, Helen L. Reeves et al. Nature Communications
  13. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis (2017)
    Oliver Krenkel, Tobias Puengel et al. Hepatology
  14. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma (2014)
    Liu Yl, Gillian Patman et al. Journal of Hepatology
  15. Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests (2021)
    Mojgan Masoodi, Amalia Gastaldelli et al. Nature Reviews Gastroenterology & Hepatology
  16. Metabolic risk factors and incident advanced liver disease in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis of population-based observational studies (2020)
    Helen Jarvis, Dawn Craig et al. PLoS Medicine
  17. Prognostic accuracy of FIB‐4, NAFLD fibrosis score and APRI for NAFLD‐related events: A systematic review (2020)
    Jenny Lee, Yasaman Vali et al. Liver International
  18. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (2024)
    Arun J. Sanyal, Pierre Bédossa et al. New England Journal of Medicine
  19. The Global Burden of Liver Disease (2023)
    Zobair M. Younossi, Grace Lai–Hung Wong et al. Clinical Gastroenterology and Hepatology
  20. Current therapies and new developments in NASH (2022)
    Jean‐François Dufour, Quentin M. Anstee et al. Gut
  21. The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): A systematic review and meta-analysis (2022)
    Linda Errington, John C. Mathers et al. Clinical Nutrition
  22. Impact of non-invasive biomarkers on hepatology practice: Past, present and future (2022)
    Quentin M. Anstee, Laurent Castéra et al. Journal of Hepatology
  23. A researcher’s guide to preclinical mouse NASH models (2022)
    Suchira Gallage, Jose Efren Barragan Avila et al. Nature Metabolism
  24. Cenicriviroc Lacked Efficacy to Treat Liver Fibrosis in Nonalcoholic Steatohepatitis: AURORA Phase III Randomized Study (2023)
    Quentin M. Anstee, Brent A. Neuschwander‐Tetri et al. Clinical Gastroenterology and Hepatology
  25. A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures (2023)
    Olivier Govaere, Leigh Alexander et al. Nature Metabolism
  26. New and emerging treatments for metabolic dysfunction-associated steatohepatitis (2024)
    Monica A. Tincopa, Quentin M. Anstee et al. Cell Metabolism

Immediate Impact

5 from Science/Nature 212 standout
Sub-graph 1 of 16

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
2025 Standout
121 intermediate papers

Works of Quentin M. Anstee being referenced

Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis
2021
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis
2018
and 62 more

Author Peers

Author Last Decade Papers Cites
Quentin M. Anstee 18861 8645 7626 247 22.8k
Geoffrey C. Farrell 19440 9801 6780 213 25.5k
Leon A. Adams 18336 8886 7643 198 22.2k
Mary E. Rinella 17635 7139 7399 127 20.4k
Michael Charlton 18908 12598 6056 247 24.5k
Brent A. Neuschwander‐Tetri 24212 9883 10995 186 29.7k
Christopher P. Day 22363 9924 9677 183 30.3k
Ariel E. Feldstein 16818 6164 6567 218 26.3k
Paul Angulo 21596 11575 9010 155 25.9k
Elisabetta Bugianesi 26731 10190 12431 282 31.7k
Matthew M. Yeh 13136 5819 4449 127 16.7k

All Works

Loading papers...

Rankless by CCL
2026